ADSTEM Inj. not checked

EHL Bio Co., Ltd.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
2 active
2 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Two 5mL of the following study drug is pre-mixed with 320mL of 0.9% normal saline is injected intravenously twice for the duration of the study. Treatment group: ADSTEM Inj. 0.5x10\^8 cells/5mL”In the company’s words, NCT04137562 on ClinicalTrials.gov
Tested for
Atopic Dermatitis (2 trials)
Main trialPhase 3
“Study of ADSTEM Injection for Patients with Moderate to Severe Subacute and Chronic Atopic Dermatitis”In the company’s words, NCT07377838 on ClinicalTrials.gov

Other drugs for Atopic Dermatitis

All 90 drugs for Atopic Dermatitis

Coming up1

Changes2

Last 90 days

Trials2

TrialPhaseCompletesWhat it tests
Phase 3Recruiting Sep 2029 Study of ADSTEM Injection for Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis
Phase 2Active, not recruiting 26 Jan 2023 Safety and Efficacy in Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow ADSTEM Inj.

Following is part of Solo: you see every change to ADSTEM Inj. the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in